Search

Your search keyword '"Lehman, Anna"' showing total 420 results

Search Constraints

Start Over You searched for: Author "Lehman, Anna" Remove constraint Author: "Lehman, Anna"
420 results on '"Lehman, Anna"'

Search Results

1. Bi-allelic ATG4D variants are associated with a neurodevelopmental disorder characterized by speech and motor impairment

2. Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann–Pick disease types A, B and A/B)

4. Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study

5. Unique variants in CLCN3, encoding an endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental disorders

7. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders.

8. Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients.

10. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy

11. Missense Variants in the Histone Acetyltransferase Complex Component Gene TRRAP Cause Autism and Syndromic Intellectual Disability.

12. Return of Results Policies for Genomic Research: Current Practices and the Hearts in Rhythm Organization (HiRO) Approach

14. Naturally occurring splice variants dissect the functional domains of BHC80 and emphasize the need for RNA analysis.

15. PIGG variant pathogenicity assessment reveals characteristic features within 19 families

18. FollowME Fabry Pathfinders Registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years

19. Glycosphingolipid evaluation for Fabry disease patients receiving migalastat after switching from enzyme replacement therapy

21. Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study

22. The management and clinical outcomes of pregnancies in women with urea cycle disorders: A review of the literature and results of an international survey

24. JARID2 haploinsufficiency is associated with a clinically distinct neurodevelopmental syndrome

25. Clinical, Neuroimaging, and Metabolic Footprint of the Neurodevelopmental Disorder Caused by Monoallelic HK1 Variants.

26. Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy

27. A germline heterozygous dominant negativeIKZF2variant causing syndromic primary immune regulatory disorder and ICHAD

29. Increased Ca 2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction

30. Hypogonadotropic Hypogonadism in Males with Glycogen Storage Disease Type 1

32. RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit—successes and challenges

35. Generation of tandem alternative splice acceptor sites andCLTChaploinsufficiency: A cause ofCLTC‐related disorder

36. Impact of Variation in Practice in the Prenatal Reporting of Variants of Uncertain Significance by Commercial Laboratories: Need for Greater Adherence to Published Guidelines

37. Dominant Negative Variants in IKZF2 Cause ICHAD Syndrome, a New Disorder Characterized by Immunodysregulation, Craniofacial Anomalies, Hearing Impairment, Athelia, and Developmental Delay

38. First reports of primary ciliary dyskinesia caused by a shared DNAH11 allele in Canadian Inuit

40. NOTCH1loss of the TAD and PEST domain: An antimorph?

44. FollowME Fabry Pathfinders registry: Renal effectiveness in a multi-national, multi-center cohort of patients on migalastat treatment for at least three years

45. Consensus clinical management guidelines for Acid Sphingomyelinase Deficiency (Niemann-Pick disease types A, B and A/B)

48. Generation of tandem alternative splice acceptor sites and CLTC haploinsufficiency: A cause of CLTC‐related disorder.

49. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

50. NOTCH1 loss of the TAD and PEST domain: An antimorph?

Catalog

Books, media, physical & digital resources